<DOC>
	<DOCNO>NCT01321957</DOCNO>
	<brief_summary>The primary objective study evaluate efficacy Irinotecan combination FOLFOX+Bevacizumab versus FOLFOX+Bevacizumab alone first-line treatment patient metastatic colorectal cancer .</brief_summary>
	<brief_title>Efficacy FOLFOX+Bevacizumab Combination With Irinotecan Treatment Metastatic Colorectal Cancer</brief_title>
	<detailed_description>5-Fluorouracil oxaliplatin ( FOLFOX-Regimen ) combination bevacizumab regard standard first-line treatment metastatic colorectal cancer [ Saltz et al. , 2008 ] . Current study establish role FOLFOXIRI regimen [ Souglakos et al. , 2006 , Falcone et al. , 2007 ] . A intensification therapy seem feasible yield response rate 84 % disease control rate 100 % [ Falcone , 2008 , Santomaggio , 2009 , Masi , 2010 ] . This trial evaluate activity intensify first-line therapy metastatic colorectal cancer compare standard treatment .</detailed_description>
	<mesh_term>Colorectal Neoplasms</mesh_term>
	<mesh_term>Bevacizumab</mesh_term>
	<mesh_term>Oxaliplatin</mesh_term>
	<mesh_term>Irinotecan</mesh_term>
	<mesh_term>Camptothecin</mesh_term>
	<mesh_term>Fluorouracil</mesh_term>
	<criteria>1 . Patients histologically confirm diagnosis stage IV ( UICC ) colorectal cancer ( primary tumor may present ) 2 . Patients least one measurable lesion , size &gt; 1 cm ( RECIST v1.1 ) 3 . ECOG Performance status ≤ 2 ( ECOG 2 , tumor relate ) 4 . Patients , able tolerate intensive first lien treatment judge investigator 5 . Life expectancy &gt; 3 month 6 . Age ≥ 18 year 7 . Haematologic function : ANC ≥ 1.5 x 109/L , platelet ≥ 100 x109/L , hemoglobin 9 g/dl 5.59 mmol/l 8 . Patients receive therapeutic anticoagulation must INR &lt; 1.5 ULN aPTT &lt; 1.5 ULN within 7 day prior registration . The use full dose anticoagulant allow long INR aPTT within therapeutic limit ( accord medical standard institution ) patient stable dose anticoagulant least two week time registration . 9 . Adequate liver function measure serum transaminase ( AST &amp; ALT ) ≤ 2.5 x ULN ( case liver metastases &lt; 5 x ULN ) total bilirubin ≤ 1.5 x ULN 10 . Adequate renal function : Serum creatinine ≤ 1.5 x ULN 11 . Signed , write informed consent 1 . Patients histologically confirm diagnosis stage IV ( UICC ) colorectal cancer ( primary tumor may present ) 2 . Patients least one measurable lesion , size &gt; 1 cm ( RECIST v1.1 ) 3 . ECOG Performance status ≤ 2 ( ECOG 2 , tumor relate ) 4 . Patients , able tolerate intensive first lien treatment judge investigator 5 . Life expectancy &gt; 3 month 6 . Age ≥ 18 year 7 . Haematologic function : ANC ≥ 1.5 x 109/L , platelet ≥ 100 x109/L , hemoglobin 9 g/dl 5.59 mmol/l 8 . Patients receive therapeutic anticoagulation must INR &lt; 1.5 ULN aPTT &lt; 1.5 ULN within 7 day prior registration . The use full dose anticoagulant allow long INR aPTT within therapeutic limit ( accord medical standard institution ) patient stable dose anticoagulant least two week time registration . 9 . Adequate liver function measure serum transaminase ( AST &amp; ALT ) ≤ 2.5 x ULN ( case liver metastases &lt; 5 x ULN ) total bilirubin ≤ 1.5 x ULN 10 . Adequate renal function : Serum creatinine ≤ 1.5 x ULN 11 . Signed , write informed consent</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>October 2016</verification_date>
</DOC>